Press Releases - Pfizer
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
As sales soared industry-wide in Q3, Pfizer moved into top spot
4 天之前 · The performance took even Pfizer by surprise as it boosted its annual revenue projection by $1.5 billion on both ends to a new range of $61 billion to $64 billion.
Newsroom - Pfizer
Pfizer Inc. today introduced PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across the U.S. Our mission to make breakthroughs that change patients’ …
Pfizer Announces New Chief Scientific Officer and President, …
NEW YORK, November 20, 2024--Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as ...
Pfizer rolls out another cost-cutting program, sets $1.5 billion …
2024年5月22日 · U.S. drugmaker Pfizer on Wednesday launched a new multi-year program to reduce its expenses by about $1.5 billion by the end of 2027, adding on to a $4 billion cost cutting plan it announced last...
Pfizer Announces Additional Phase 2/3 Study Results Confirming …
2021年12月14日 · Final data available from all high-risk patients enrolled in EPIC-HR study (n= 2,246) confirmed prior results of interim analysis showing PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) reduced risk of hospitalization or death by 89% (within three days of symptom onset) and 88% (within five days of symptom onset) compared to …
Pfizer lifts profit forecast as investors await turnaround
July 30 (Reuters) - Pfizer (PFE.N) raised its annual profit forecast on Tuesday, helped by cancer treatments acquired through a $43 billion deal for Seagen and strong sales of its heart disease...
Stories & News - Pfizer Investor Insights
News. November 20, 2024. Pfizer Announces New Chief Scientific Officer and President, Research & Development; November 20, 2024. European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors; November 14, 2024
CDC identifies possible safety issue with Pfizer’s updated ... - CNN
2023年1月13日 · The US Centers for Disease Control and Prevention said Friday that there is a possible safety issue with the bivalent Covid-19 vaccine made by Pfizer and BioNTech but that it is unlikely to...
Pfizer lifts profit view on cost cuts, demand for COVID products
2024年5月1日 · Pfizer lifted its annual earnings forecast on Wednesday and reported a first-quarter profit above Wall Street estimates, boosted by cost cutting efforts and stronger-than-expected sales of its...